FDG PET for the detection of bone metastases: Sensitivity, specificity and comparison with other imaging modalities

PET Clinics

Volumn 5, Issue 3, 2010, Pages 281-295

  Costelloe, Colleen M ^a   Chuang, Hubert H ^a   Madewell, John E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone; FDG; Metastases; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM;

ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; ISOTOPE TRACING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 79954590144     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2010.04.001     Document Type: Article

References (52)

1. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22:2942-53. (Pubitemid 41079914)
2. Galasko CS. Skeletal metastases and mammary cancer. Ann R Coll Surg Engl 1972;50:3-28.
3. Edelstyn GA, Gillespie PJ, Grebbell FS. The radiological demonstration of osseous metastases. Experimental observations. Clin Radiol 1967;18: 158-62.
4. Cook GJ, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med 1999;29:69-79. (Pubitemid 29061432)
5. Hortobagyi GN, Libshitz HI, Seabold JE. Osseous metastases of breast cancer. Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy. Cancer 1984;53:577-82. (Pubitemid 14182740)
6. Perez DJ, Powles TJ, Milan J, et al. Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet 1983;2:613-6. (Pubitemid 13051051)
7. Mahner S, Schirrmacher S, BrennerW, et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 2008;19:1249-54. (Pubitemid 351911953)
8. Costelloe CM, Murphy WA Jr, Chasen BA. Musculoskeletal pitfalls in 18F-FDG PET/CT: pictorial review. AJR Am J Roentgenol 2009;193:WS1-13 [quiz S26-30].
9. Bastiaannet E, Wobbes T, Hoekstra OS, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009; 27:4774-80.
10. Kleis M, Daldrup-Link H, Matthay K, et al. Diagnostic value of PET/CT for the staging and restaging of FDG PET for the Detection of Bone Metastases 293 pediatric tumors. Eur J Nucl Med Mol Imaging 2009; 36:23-36.
11. Ellis RE. The distribution of active bone marrow in the adult. Phys Med Biol 1961;5:255-8.
12. Kazama T, Swanston N, Podoloff DA, et al. Effect of colony-stimulating factor and conventional- or highdose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 2005;32:1406-11. (Pubitemid 41746844)
13. Chiang SB, Rebenstock A, Guan L, et al. Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging. Clin Nucl Med 2003;28:674-6. (Pubitemid 38281902)
14. Arano Y. Recent advances in 99 mTc radiopharmaceuticals. Ann Nucl Med 2002;16:79-93.
15. Loeffler RK, DiSimone RN, Howland WJ. Limitations of bone scanning in clinical oncology. JAMA 1975; 234:1228-32.
16. Corcoran RJ, Thrall JH, Kyle RW, et al. Solitary abnormalities in bone scans of patients with extraosseous malignancies. Radiology 1976;121:663-7.
17. Costelloe CM, Rohren EM, Madewell JE, et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 2009;10:606-14.
18. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53. (Pubitemid 41095099)
19. Kato H, Miyazaki T, Nakajima M, et al. Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas. Anticancer Res 2005;25:4439-44. (Pubitemid 41729493)
20. Ohta M, Tokuda Y, Suzuki Y, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 2001;22:875-9. (Pubitemid 32681625)
21. Kut V, Spies W, Spies S, et al. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol 2007;30:45-50. (Pubitemid 46213824)
22. Du Y, Cullum I, Illidge TM, et al. Fusion of metabolic function and morphology: sequential [18F]fluoro deoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007;25:3440-7. (Pubitemid 47310881)
23. Abe K, Sasaki M, Kuwabara Y, et al. Comparison of 18FDG-PET with 99 mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005;19:573-9. (Pubitemid 43161842)
24. Gayed I, Vu T, Johnson M, et al. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol 2003;5:26-31. (Pubitemid 36596542)
25. Nagaoka S, Itano S, Ishibashi M, et al. Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int 2006;26:781-8. (Pubitemid 44165245)
26. Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510-5 [discussion: 515-6].
27. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314-9.
28. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-7. (Pubitemid 30262739)
29. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36: 1811-7.
30. Min JW, Um SW, Yim JJ, et al. The role of wholebody FDG PET/CT, Tc 99 m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci 2009;24:275-80.
31. Zimmer WD, Berquist TH, McLeod RA, et al. Bone tumors: magnetic resonance imaging versus computed tomography. Radiology 1985;155:709-18. (Pubitemid 15044776)
32. Ak I, Sivrikoz MC, Entok E, et al. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. Eur J Cardiothorac Surg 2010;37(4):792-6.
33. Uematsu T, Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 2005;184:1266-73. (Pubitemid 43821911)
34. Yoon KT, Kim JK, Kim do Y, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 2007;72(Suppl 1):104-10. (Pubitemid 350256673)
35. Ng SH, Chan SC, Yen TC, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging 2009;36:12-22.
36. Colman LK, Porter BA, Redmond J 3rd, et al. Early diagnosis of spinal metastases by CT and MR studies. J Comput Assist Tomogr 1988;12:423-6.
37. Algra PR, Bloem JL, Tissing H, et al. Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radiographics 1991;11:219-32.
38. Liu FY, Yen TC, Chen MY, et al. Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging. Cancer 2009;115:5470-80.
39. Ma J, Costelloe CM, Madewell JE, et al. Fast Dixonbased multisequence and multiplanar MRI for whole-body detection of cancer metastases. J Magn Reson Imaging 2009;29:1154-62.
40. Engelhard K, Hollenbach HP, Wohlfart K, et al. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 2004;14:99-105. (Pubitemid 38181060)
41. Eustace S, Tello R, DeCarvalho V, et al. A comparison of whole-body turboSTIR MR imaging and planar 99 mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol 1997; 169:1655-61. (Pubitemid 127469800)
42. Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusionweighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 2009;30:298-308.
43. Schmidt GP, Schoenberg SO, Schmid R, et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 2007;17:939-49. (Pubitemid 46766875)
44. Schmidt GP, Baur-Melnyk A, Herzog P, et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol 2005;40: 743-53. (Pubitemid 41690430)
45. Schmidt GP, Baur-Melnyk A, Haug A, et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol 2008; 65:47-58.
46. Ohno Y, Koyama H, Nogami M, et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging 2007;26:498-509. (Pubitemid 350194569)
47. Ito S, Kato K, Ikeda M, et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 2007;48: 889-95. (Pubitemid 46909916)
48. Liu FY, Chang JT, Wang HM, et al. [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 2006;24:599-604. (Pubitemid 46630422)
49. Kim MR, Roh JL, Kim JS, et al. 18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy for detecting bone metastases in patients with malignancies of the upper aerodigestive tract. Oral Oncol 2008;44:148-52. (Pubitemid 351179658)
50. Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003;38:250-6. (Pubitemid 36535030)
51. Dose J, Bleckmann C, Bachmann S, et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002;23:857-64.
52. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003;290: 3199-206. (Pubitemid 38020681)